Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Bruce Mitlak
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Concepts & Ideas
Disorders
Procedures
Physiology
Anatomy
Sign-in to see full Profile
Network (preview)
6
Delmas, Pierre
6
Reginster, Jean-Yves
6
Cohen, Fredric
4
Laslop, Andrea
4
Christiansen, Claus
4
Harper, Kristine
3
Heath, H
3
Huster, WJ
3
Ethgen, Dominique
3
Bjarnason, Nina
3
Kaufman, Jean-Marc
3
Kreutz, Gottfried
3
Tsouderos, Yannis
3
Wang, Ouhong
2
Zanchetta, Jose
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Bruce Mitlak (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Davis Gregory C; Beals John M; Johnson Craig; Mayer Mark H; Meiklejohn Bruce I; Mitlak Bruce H; Roth Jody L; Towns John K; Veenhuizen Melissa
Recommendations regarding technical standards for follow-on biologics: comparability, similarity, interchangeability.
Current medical research and opinion 2009;25(7):1655-61.
-
2009: Bouxsein Mary L; Chen Peiqi; Glass Emmett V; Kallmes David F; Delmas Pierre D; Mitlak Bruce H
Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
The Journal of bone and joint surgery. American volume 2009;91(6):1329-38.
-
2008: Goldhahn Jörg; Scheele Wim H; Mitlak Bruce H; Abadie Eric; Aspenberg Per; Augat Peter; Brandi Maria-Luisa; Burlet Nansa; Chines Arkadi; Delmas Pierre D; Dupin-Roger Isabelle; Ethgen Dominique; Hanson Beate; Hartl Florian; Kanis John A; Kewalramani Reshma; Laslop Andrea; Marsh David; Ormarsdottir Sif; Rizzoli René; Santora Art; Schmidmaier Gerhard; Wagener Michael; Reginster Jean-Yves
Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis.
Bone 2008;43(2):343-7.
-
2007: Lekkerkerker F; Kanis J A; Alsayed N; Bouvenot G; Burlet N; Cahall D; Chines A; Delmas P; Dreiser R-L; Ethgen D; Hughes N; Kaufman J-M; Korte S; Kreutz G; Laslop A; Mitlak B; Rabenda V; Rizzoli R; Santora A; Schimmer R; Tsouderos Y; Viethel P; Reginster J-Y;
Adherence to treatment of osteoporosis: a need for study.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2007;18(10):1311-7.
-
2007: Harper Kristine D; Krege John H; Marcus Robert; Mitlak Bruce H
Osteosarcoma and teriparatide?
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2007;22(2):334.
-
2007: Keaveny Tony M; Donley David W; Hoffmann Paul F; Mitlak Bruce H; Glass Emmett V; San Martin Javier A
Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2007;22(1):149-57.
-
2006: Harper Kristine D; Krege John H; Marcus Robert; Mitlak Bruce H
Comments on Initial experience with teriparatide in the United States.
Current medical research and opinion 2006;22(10):1927.
-
2006: Reginster Jean-Yves; Abadie Eric; Delmas Pierre; Rizzoli René; Dere Willard; der Auwera Philippevan; Avouac Bernard; Brandi Maria-Luisa; Daifotis Anastasia; Diez-Perez Adolfo; Calvo Gonzalo; Johnell Olof; Kaufman Jean-Marc; Kreutz Gottfried; Laslop Andrea; Lekkerkerker Fritz; Mitlak Bruce; Nilsson Per; Orloff John; Smillie Mary; Taylor Andrew; Tsouderos Yannis; Ethgen Dominique; Flamion Bruno
Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2006;17(1):1-7.
-
2005: Prince Richard; Sipos Adrien; Hossain Anwar; Syversen Unni; Ish-Shalom Sophia; Marcinowska Ewa; Halse Johan; Lindsay Robert; Dalsky Gail P; Mitlak Bruce H
Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2005;20(9):1507-13.
-
2005: Abadie Eric C; Devogealer Jean-Pierre; Ringe Johann D; Ethgen Dominique J; Bouvenot Gilles M; Kreutz Gottfried; Laslop Andrea; Orloff John J; Vanderauwera Philippe M; Delmas Pierre D; Dere Willard H; Branco Jaime; Altman Roy D; Avouac Bernard P; Menkes Charles J; Vanhaelst Luc; Mitlak Bruce H; Tsouderos Yannis; Reginster Jean-Yves L
Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science.
Seminars in arthritis and rheumatism 2005;35(1):1-4.
-
2005: Kaufman J-M; Orwoll E; Goemaere S; San Martin J; Hossain A; Dalsky G P; Lindsay R; Mitlak B H
Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2005;16(5):510-6.
-
2005: Alkhiary Yaser M; Gerstenfeld Louis C; Krall Elizabeth; Westmore Michael; Sato Masahiko; Mitlak Bruce H; Einhorn Thomas A
Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34).
The Journal of bone and joint surgery. American volume 2005;87(4):731-41.
-
2004: Lindsay Robert; Scheele Wim H; Neer Robert; Pohl Gerhardt; Adami Silvano; Mautalen Carlos; Reginster Jean-Yves; Stepan Jan J; Myers Stephen L; Mitlak Bruce H
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
Archives of internal medicine 2004;164(18):2024-30.
-
2003: Jiang Yebin; Zhao Jenny J; Mitlak Bruce H; Wang Ouhong; Genant Harry K; Eriksen Erik F
Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2003;18(11):1932-41.
-
2003: Marcus Robert; Wang Ouhong; Satterwhite Julie; Mitlak Bruce
The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2003;18(1):18-23.
-
2002: Mitlak Bruce H
Parathyroid hormone as a therapeutic agent.
Current opinion in pharmacology 2002;2(6):694-9.
-
2002: Hockett Richard D; Kirkwood Sandra C; Mitlak Bruce H; Dere Willard H
Pharmacogenomics in endocrinology.
The Journal of clinical endocrinology and metabolism 2002;87(6):2495-9.
-
2002: Sarkar Somnath; Mitlak Bruce H; Wong Mayme; Stock John L; Black Dennis M; Harper Kristine D
Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2002;17(1):1-10.
-
2001: Neer R M; Arnaud C D; Zanchetta J R; Prince R; Gaich G A; Reginster J Y; Hodsman A B; Eriksen E F; Ish-Shalom S; Genant H K; Wang O; Mitlak B H
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
The New England journal of medicine 2001;344(19):1434-41.
-
2001: Bjarnason N H; Sarkar S; Duong T; Mitlak B; Delmas P D; Christiansen C
Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2001;12(11):922-30.
-
2000: Johnston C C; Bjarnason N H; Cohen F J; Shah A; Lindsay R; Mitlak B H; Huster W; Draper M W; Harper K D; Heath H; Gennari C; Christiansen C; Arnaud C D; Delmas P D
Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials.
Archives of internal medicine 2000;160(22):3444-50.
-
1999: Ettinger B; Black D M; Mitlak B H; Knickerbocker R K; Nickelsen T; Genant H K; Christiansen C; Delmas P D; Zanchetta J R; Stakkestad J; Glüer C C; Krueger K; Cohen F J; Eckert S; Ensrud K E; Avioli L V; Lips P; Cummings S R
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
JAMA : the journal of the American Medical Association 1999;282(7):637-45.
-
1999: Heath H; Mitlak B; Anderson P
Update in endocrinology.
Annals of internal medicine 1999;131(4):309.
-
1999: Mitlak B H; Cohen F J
Selective estrogen receptor modulators: a look ahead.
Drugs 1999;57(5):653-63.
-
1999: Davies G C; Huster W J; Shen W; Mitlak B; Plouffe L; Shah A; Cohen F J
Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women.
Menopause (New York, N.Y.) 1999;6(3):188-95.
-
1998: Cohen F J; Eckert S; Mitlak B H
Geographic differences in bone turnover: data from a multinational study in healthy postmenopausal women.
Calcified tissue international 1998;63(4):277-82.
-
1998: Bryant H U; Kauffman R F; Iversen P; Cox D A; Mitlak B H; Heath H
Comment on lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys.
The Journal of clinical endocrinology and metabolism 1998;83(8):3001-4.
-
1997: Delmas P D; Bjarnason N H; Mitlak B H; Ravoux A C; Shah A S; Huster W J; Draper M; Christiansen C
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.
The New England journal of medicine 1997;337(23):1641-7.
-
1997: Mitlak B H; Cohen F J
In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators.
Hormone research 1997;48(4):155-63.
Sign-in to see more
